Arura Pharma

Arura Pharma is a pre-clinical stage biotechnology company dedicated to the discovery and development of small molecule modulators of the Pregnane X Receptor (PXR). The company's research focuses on two primary therapeutic areas: oncology, where PXR inhibition is used to overcome drug resistance in solid tumors, and gastroenterology, where PXR modulation is explored for treating inflammatory bowel disease (IBD). As a spin-off from the Albert Einstein College of Medicine, Arura Pharma utilizes proprietary insights into nuclear receptor biology to develop first-in-class therapies. Their lead programs are currently in the pre-clinical phase, aiming to improve patient outcomes in complex diseases with high unmet medical needs.